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ABSTRACT
Prevention and management of cytomegalovirus (CMV) disease after hematopoietic stem cell transplantation
(HSCT) is critically important, but clinical practices have historically been heterogeneous. The Centers for Disease
Control (CDC), as part of a larger clinical practice guideline initiative, has published evidence-based recommen-
dations, but their effect on clinical practice has not been assessed. A survey was sent to all CanadianHSCT program
directors to describe current practices. Current practices were subsequently compared with CDC guideline
recommendations and with a Canadian survey published before the CDC guidelines. When current practices did
not conform to guideline recommendations, a literature review was performed to determine whether current
practices were supported by evidence published after the CDC guidelines. The survey response rate was 100%.
Variability in practices was observed in several aspects of patient care, including (1) indications for CMV-negative
blood products, (2) surveillance tests used to detect CMV infection, (3) duration of surveillance testing, (4) duration
of maintenance treatment after preemptive therapy was initiated, and (5) treatment of CMV disease. Overall
adherence to guideline recommendations was good, especially when they were supported by high-quality data.
However, deviations from guideline recommendations were observed: (1) most Canadian allogeneic programs used
shorter courses of preemptive therapy; (2) prevention measures aimed at late CMV disease were not systematically
applied at most allogeneic programs; and (3) most autologous HSCT programs did not administer preemptive
therapy even in high-risk recipients. When deviations occurred, recent evidence supported current practices in
some instances (shorter courses of preemptive therapy) but not in others (absence of strategies to prevent late CMV
disease). Compared with practices in Canada before publication of the CDC guidelines, a higher proportion of
programs used CDC-recommended surveillance tests and treatment for CMV infection. Current practices in
Canada remain heterogeneous. Discrepancies between current practices and CDC guideline recommendations
occurred in situations either in which practices had changed in response to recently published data or in which
evidence supporting a recommendation was poor. These results suggest an urgent need for the development of
well-designed clinical trials. Incorporation of recent data into updated guidelines may be appropriate.
© 2004 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Cytomegalovirus (CMV) infection after hemato-
oietic stem cell transplantation (HSCT) is associated C
B&MTith signiﬁcant morbidity, decreased patient survival,
nd considerable cost to health-care systems. Most
nfections are accounted for either by reactivation of
MV in seropositive recipients or by primary infec-
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2ion transmitted by transfusion of CMV-positive
lood products (including the marrow graft) to sero-
egative recipients [1]. Infection, which is deﬁned as
symptomatic circulating virus, occurs in up to 80% of
t-risk patients a median of 6 to 8 weeks after HSCT
1-5]. In the setting of allogeneic HSCT, approxi-
ately one third of these patients subsequently de-
elop symptomatic CMV disease, most often pneumo-
itis, which is associated with poor response to
reatment and signiﬁcant mortality [4-10]. In contrast,
p to 5% of patients who are treated with autologous
SCT develop CMV disease even though they have a
imilarly high incidence of CMV infection [3,11,12].
he economic effect of effective screening, preven-
ion, and treatment of CMV infection is considerable
nd contributes signiﬁcantly to the overall costs of
llogeneic HSCT [13].
CMV disease is difﬁcult to treat with currently
vailable therapies. Intravenous (IV) ganciclovir, alone
r in combination with IV immune globulin (IVIG),
he usual ﬁrst-line treatment for CMV disease, is often
nsuccessful, and 30% to 70% of patients with CMV
neumonitis succumb to their illness [6,7,9,10,14].
herefore, efforts have focused on the prevention and
reatment of CMV infection. Transfusion of CMV-
eronegative blood products provides an opportunity
o prevent CMV infection in seronegative HSCT re-
ipients [1,10,15,16]. CMV seropositive blood prod-
cts can be rendered safe by eliminating the reservoir
f latent CMV infection in blood mononuclear cells
hrough prestorage leukodepletion [10,16-18].
The development of effective antiviral therapies
as ushered in a new paradigm in the treatment of
MV infection. Currently, 2 antiviral preventive
trategies dominate clinical practice: prophylaxis and
reemptive therapy. Prophylaxis regimens are initi-
ted at the time of engraftment and continued until at
east day 100. In contrast, preemptive therapy is ini-
iated in asymptomatic patients only after a positive
creening test for circulating virus is obtained. The
uccess of both prophylactic and preemptive ap-
roaches is suggested by a decreasing incidence of
MV disease, demonstrated mostly in sibling donor
ransplants [4,5,8,19,20]. Although a positive effect of
reemptive therapy is not contested, the effectiveness
f prophylaxis is less easy to evaluate because of the
ompeting toxicity of ganciclovir (myelosuppression
nd consequently increased infection-related morbid-
ty) [4,5,8,19,21].
Despite the publication of several large, well-de-
igned clinical trials, there remains a lack of consensus
egarding many aspects of care necessary to prevent
MV disease after HSCT. This has led to wide vari-
tion in clinical practices among transplant centers in
orth America, as documented in 2 published multi-
enter surveys, 1 of which was performed in Canada
22,23]. Recently, the Centers for Disease Control a
88CDC), as part of a larger clinical practice guideline,
valuated the available literature to derive evidence-
ased recommendations for the prevention, screening,
iagnosis, and treatment of CMV infection and dis-
ase [24]. Whether these guidelines have had an effect
n current practice has not yet been assessed.
To evaluate the effect of the CDC guidelines on
urrent practices in Canada, we administered a survey
o directors of HSCT with the following objectives:
1) to describe current practices relating to the diag-
osis, prevention, and treatment of CMV infection
nd disease; (2) to determine whether current prac-
ices conform to the CDC guideline recommenda-
ions; (3) to compare current practices (as of May
002) with practices before publication of the CDC
uideline recommendations; and (4) to determine
hether practices that do not adhere to guideline
ecommendations are supported by data that became
vailable after the publication of the CDC recommen-
ations. All centers that participated in this study are
embers of the Canadian Blood and Marrow Trans-
lant Group.
ETHODS
This study was prompted by a request for a pre-
entation on CMV infection at the biennial meeting of
he Canadian Blood and Marrow Transplant Group in
ay 2002. Thus, in February 2002, a questionnaire
as sent by e-mail to all 25 Canadian bone marrow
ransplant centers listed by the Canadian Blood and
arrow Transplant Group; it inquired about current
ractices in surveillance, prophylaxis, and treatment of
MV infection. The initial request was followed in a
ew cases by further e-mail and telephone reminders.
ll 25 centers responded by May 2002. The survey
onsisted of a single page of questions requiring re-
pondents to check appropriate boxes. Space was pro-
ided for qualifying statements. All questions ad-
ressed practices for allogeneic and autologous
ransplantation separately. Data were analyzed by us-
ng SPSS version 11.0 (SPSS Inc., Chicago, IL).
Survey responses were compared with published
DC guideline recommendations [24]. In addition,
esponses were compared with results from a ques-
ionnaire administered to Canadian transplant centers
n January 1998 (before the CDC guideline recom-
endations). The previous survey, published in 1999,
as designed to gather information about CMV dis-
ase prevention and treatment practices in Canada at
hat time [23].
ESULTS
articipating Centers
The 25 centers included 25 autologous and 21
llogeneic HSCT programs. Twelve programs treated
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CMV Prophylaxis and Treatment after HSCT in Canada
Bediatric patients (6 allogeneic; 6 autologous), and 34
rograms treated adult patients (19 autologous; 15
llogeneic) exclusively. The survey response rate
100%) permitted a comprehensive analysis of CMV
revention and treatment practices in all allogeneic
nd autologous HSCT programs. CMV prevention
nd treatment strategies often differ in the allogeneic
nd autologous settings because of a much lower rate
f CMV disease in the latter. Therefore, survey results
or allogeneic and autologous HSCT programs are
resented separately.
llogeneic Transplantation
Pretransplantation CMV serology and management of
MV-negative blood products. Before allogeneic HSCT,
ll 21 programs (15 adult; 6 pediatric) assessed pre-
ransplantation CMV serologic status (immunoglob-
lin G anti-CMV) in both the donor and the recipi-
nt. All programs reported using CMV-negative
lood products; however, there was variability regard-
ng the indications according to donor/recipient pair
erologic status (Table 1). Most programs transfused
MV-negative blood products selectively, either to
MV-seronegative recipients regardless of pretrans-
lantation donor CMV serologic status (D//R; 11
enters; 52%) or to CMV-seronegative recipients of a
MV-seronegative donor (D/R; 6 centers; 29%). A
inority of programs (4 centers; 19%) transfused
MV-negative blood products to all patients regard-
ess of donor/recipient pair CMV serologic status.
ractices were similar among adult and pediatric
ransplant programs.
Surveillance for CMV infection. Patients in all allo-
eneic HSCT programs were placed on a surveillance
able 1. Administration of CMV-Seronegative Blood Products by
llogeneic HSCT Programs According to Donor/Recipient (D/R)
air CMV Serologic Status
D/R
n (%)
D//R
n (%)
All Patients*
n (%)
ll centers 6/21 (29) 11/21 (52) 4/21 (19)
dult programs 5/15 (33.3) 8/15 (53.3) 2/15 (13.3)
ediatric programs 1/6 (16.7) 3/6 (50) 2/6 (33.3)*
One center transfused CMV-negative blood products when either
the donor or recipient was CMV seronegative (ie, DR,
D/R, D/R).
able 2. Test Strategies Used to Detect CMV Infection after Allogeneic
CMV pp65
Antigen PCR BAL
ll centers 10/21 (46) 6/21 (28.6) 1/21 (5)
dult programs 8/15 (53.3) 5/15 (33.3) 1/15 (6.
ediatric programs 2/6 (33.3) 2/6 (33.3) 0/6 (0)B&MTnd treatment protocol to prevent CMV disease. A
ariety of testing strategies were used to detect CMV
nfection after transplantation (Table 2). Among
hem, CMV pp65 antigenemia (46.6%) and CMV
NA polymerase chain reaction (PCR)-based assays
28.6%) were most commonly used. Single programs
sed unique testing strategies that included bron-
hoalveolar lavage (BAL) for shell-vial testing to de-
ect early CMV antigen, nucleic acid sequence–based
mpliﬁcation (NASBA), and a variety of combination
trategies (BAL plus PCR, CMV antigen plus PCR, or
CR plus viral culture). The frequency with which
arious testing strategies were used at adult, compared
ith pediatric, programs was similar.
Monitoring for CMV infection after HSCT ex-
ended for a variable length of time among transplant
rograms (Table 3). All programs monitored for at
east 100 days after transplantation. Seven programs
33%) discontinued monitoring at day 100, compared
ith 3 programs (14%) that stopped surveillance after
20 days and 3 (14%) that stopped surveillance after
80 days. The remaining 8 allogeneic HSCT pro-
rams (38%) monitored for a variable length of time
fter 100 days, depending on the presence of risk
actors for late CMV infection (graft-versus-host dis-
ase, concurrent immunosuppressive treatment, or
oth). Results for adult and pediatric subgroups are
hown in Table 3; pediatric programs tended to ex-
end surveillance longer than adult programs.
reatment of CMV Infection and CMV Disease
Prophylactic therapy. Four programs (3 pediatric
nd 1 adult) administered prophylactic therapy to all
atients, and 1 program (adult) administered prophy-
actic therapy selectively. Among those that adminis-
ered prophylaxis, 2 pediatric centers administered
anciclovir, 1 pediatric center administered IVIG, and
adult program administered high-dose acyclovir.
rograms that administered IVIG or high-dose acy-
lovir prophylaxis also monitored for CMV infection.
preemptive course of ganciclovir without mainte-
ance therapy was administered if a positive test for
MV infection was obtained. The adult program that
dministered prophylaxis selectively used ganciclovir
or high-risk patients only (donor or recipient CMV
ositive and receiving concurrent corticosteroid ther-
Strategy Used, n (%)
NASBA BAL  PCR
CMV Antigen
 PCR
PCR  Viral
Culture
1/21 (5) 1/21 (5) 1/21 (5) 1/21 (5)
0/15 (0) 1/15 (6.7) 1/15 (6.7) 0/15 (0)
1/6 (16.7) 0/6 (0) 0/6 (0) 1/6 (16.7)HSCT
Test
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2py). Otherwise, preemptive ganciclovir was adminis-
ered until at least day 100.
Preemptive therapy. The remaining 17 allogeneic
SCT programs (81%) used a preemptive approach.
ll programs used ganciclovir as ﬁrst-line treatment
or preemptive therapy. On completion of a preemp-
ive course of therapy (2 weeks), treatment of patients
as heterogeneous (Table 4). Nine programs (53%)
iscontinued therapy if follow-up testing for CMV
nfection was negative and restarted surveillance test-
ng (ie, no maintenance therapy). In contrast, the
emaining 8 programs (47%) continued ganciclovir
aintenance therapy of variable duration (14-120
ays).
Treatment of CMV disease. CMV disease was
reated with ganciclovir alone at 12 programs (57%)
nd with IVIG in combination with ganciclovir in the
emaining 9 (43%). Treatment of CMV disease was
imilar across the subgroups of adult and pediatric
ransplant programs. No center used foscarnet as pri-
ary therapy.
dherence to CDC Recommendations and
omparison with the Previous Survey
Guideline recommendations that were assessed by
ur survey are presented in Table 5. Overall, adher-
nce to the CDC guidelines was good, particularly
hen evidence supporting the recommendation was
trong, although there were some variations: (1) most
rograms treated CMV infection with shorter courses
f preemptive ganciclovir despite strong evidence sup-
orting CDC recommendations for maintaining
reatment until day 100, and (2) a minority of pro-
rams (38%) routinely monitored for late CMV dis-
able 3. Duration of CMV Surveillance after Allogeneic HSCT
Duration of Surveillance, n (%)
100 d 120 d 180 d
Variable
>100 d
ll centers 7/21 (33.3) 3/21 (14%) 3/21 (14%) 8/21 (38.7)
dult
programs 7/15 (46.7) 2/15 (13.3) 1/15 (6.7) 5/15 (33.3)
ediatric
programs 0/6 (0) 1/6 (16.7) 2/6 (33.3) 3/6 (50)
able 4. Duration of Maintenance Ganciclovir after Preemptive Treatm
None 14 d 42
ll centers 9/17 (53) 2/17 (11.7) 1/17 (
dult programs 6/14 (42.9) 2/14 (14.3) 1/14 (
ediatric programs 3/3 (100) 0/3 (0) 0/3 (0
Two pediatric programs (1 administering high-dose acyclovir and
strategy to treat CMV infection. Neither used ganciclovir maintenanc
90ase. Compared with practices in Canada before pub-
ication of the CDC guidelines, more allogeneic
ransplant programs used (1) ganciclovir as the ﬁrst-
ine drug for prophylaxis or preemptive therapy of
MV infection (90% versus 73%), (2) CMV pp65
ntigenemia or PCR-based assays to monitor for
MV infection (90% versus 58%), and (3) CMV-
egative blood products for recipients of a CMV-
eropositive donor (Table 5).
uideline Adherence According to Transplanting
enter Characteristics
An attempt was made to determine whether any
enter characteristics predicted adherence to guideline
ecommendations. Analysis included (1) center size
those performing more than 50 transplantations per
ear were compared with those performing fewer than
0 transplantations per year); (2) centers performing
oth allogeneic and autologous HSCT compared with
hose performing autologous HSCT alone; and (3)
dult compared with pediatric centers. None of these
haracteristics contributed signiﬁcantly to overall
uideline adherence (data not shown). However, iso-
ated deviations from guideline recommendations
ended to occur at centers that performed fewer than
0 transplantations per year as follows: high-dose acy-
lovir and IVIG were each administered at 1 center as
rst-line therapy to prevent CMV disease, and
ASBA and BAL were each used at 1 center as mon-
toring tests for CMV infection. More pediatric allo-
eneic HSCT programs tended to monitor for late
MV disease (extended surveillance monitoring be-
ond 100 days) either routinely or in high-risk pa-
ients compared with adult programs.
utologous Transplantation
Pretransplantation CMV serology and management of
MV-negative blood products. Fifteen adult programs
79%) and 6 pediatric programs (100%) assessed re-
ipient CMV serologic status (immunoglobulin G
nti-CMV) before transplantation. Seven autologous
SCT programs (28%) did not administer CMV-
egative blood products regardless of the CMV sero-
ogic status of the recipient. Among the 18 programs
hat used CMV-negative blood products, the most
CMV Infection (Allogeneic HSCT)*
Duration, n (%)
56 d
Until 100 d
after HSCT
Until 120 d
after HSCT
Variable
Duration
1/17 (5.9) 2/17 (11.7) 1/17 (5.9) 1/17 (5.9)
1/14 (7.1) 2/14 (14.3) 1/14 (7.1) 1/14 (7.1)
0/3 (0) 0/3 (0) 0/3 (0) 0/3 (0)
nistering 1V1G prophylaxis) used a prophylaxis/preemptive hybrident of
d
5.9)
7.2)
)
1 admi
e therapy once preemptive ganciclovir was completed.
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CMV Prophylaxis and Treatment after HSCT in Canada
Bommon indication was a CMV-seronegative recipi-
nt. Practices were similar among adult and pediatric
rograms (Table 6).
Surveillance for CMV infection. Only 3 programs
12%) placed recipients of autologous HSCT on a
urveillance program to detect CMV infection (1
dult; 2 pediatric). One adult program monitored pa-
ients with CMV antigenemia testing until 180 days
fter transplantation. One pediatric program moni-
ored patients with PCR until day 180, whereas an-
ther used a combination of PCR and viral culture
ssays until at least day 100 after transplantation.
reatment of CMV Infection and CMV Disease
Prophylactic therapy. Prophylaxis was used in 2
rograms after autologous HSCT (8%). One adult
rogram administered high-dose acyclovir, and 1 pe-
iatric program used prophylactic IVIG after trans-
lantation.
Preemptive therapy. Two programs (8%) used a
reemptive approach. One adult program adminis-
able 5. Adherence to CDC Guideline Recommendations at Canadian
CDC Recommendations (2000)
onor and recipient pairs should have pretransplantation CMV
serology performed
/R pairs should receive CMV-seronegative or leukocyte-reduc
mood products
nsufficient data exist to recommend CMV-seronegative blood
products to D/R pairs
ll patients should be placed on a CMV disease prevention progr
(prophylaxis or preemptive therapy)
anciclovir is the first-line therapy for the prevention of CMV di
MV pp65 antigenemia or PCR-based assays are recommended
the diagnosis of CMV infection
nce preemptive therapy has started it should be continued unt
100 or at least 3 wk
horter courses of ganciclovir may be appropriate, but routine w
monitoring should continue after stopping therapy because rel
can occur
onitoring for CMV infection should extend beyond 100 days aft
HSCT for patients at high risk for late CMV disease
See Appendix 1.
able 6. Transfusion of CMV-Seronegative Blood Products among
utologous HSCT Programs According to Donor/Recipient Pair
MV Serologic Status
Donor-Recipient CMV
Status, n (%)
Seronegative
Recipients
All
Patients
ll centers (n  25) 16/25 (64.0) 2/25 (8.0)
dult programs (n  19) 11/19 (57.9) 1/19 (5.3)
ediatric programs (n  6) 5/6 (83.3) 1/6 (16.7)w
B&MTered a preemptive course of ganciclovir followed by
aintenance ganciclovir for a variable duration. One
ediatric program used a preemptive course of ganci-
lovir without maintenance therapy.
Treatment of CMV disease. CMV disease was
reated with ganciclovir therapy alone at 18 programs
72%) and with ganciclovir in combination with IVIG
t the remaining 7 (28%). More pediatric programs
han adult programs used the combination of IVIG
nd ganciclovir to treat CMV disease (50% versus
1%, respectively).
dherence to CDC Recommendations and
omparison with the Previous Survey
Guideline recommendations that were assessed by
ur survey are shown in Table 7. Despite generally
ood adherence, deviations from CDC guideline rec-
mmendations were observed: (1) 4 programs (16%)
id not evaluate the CMV serologic status of patients
efore autologous HSCT; (2) the vast majority of
rograms (92%) did not evaluate patients for preemp-
ive therapy despite recommendations that it be con-
idered in high-risk patients; and (3) 1 program used
igh-dose acyclovir prophylaxis despite evidence that
his approach may be harmful.
The previous survey did not speciﬁcally address
any aspects of CMV disease prevention in the au-
ologous setting. As a result, the degree to which
ractices before publication of the CDC guidelines
dhere to CDC recommendations could not be fully
valuated or compared with current practices. Prac-
ices that could be assessed with the previous survey
ic HSCT Centers: 1999 Versus 2002
Adherence to
Recommendation
(1999 Survey) (%)
Adherence to
Recommendation
(2002 Survey) (%)
Quality of Evidence
Supporting
Recommendation*
100 100 AI
100 100 AI
40 71 Not applicable
100 100 AI
73 90 BIII
58 90 AIII
Not evaluable 23.5 AI
Not evaluable 76.5 BIII
Not evaluable 67 BIIIAllogene
ed
am
sease
for
il day
eekly
apses
erere similar when compared with our survey.
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2ISCUSSION
CMV disease continues to be a major source of
atient morbidity and mortality after HSCT. In the
ast, the diagnostic, preventative, and therapeutic
ractices used to prevent CMV infection and disease
fter HSCT have varied [22,23]. Recently, a panel of
xperts under the auspices of the CDC synthesized
vidence-based guideline recommendations to help
oth physicians and transplant centers manage pa-
ients at risk for CMV infection after HSCT. To our
nowledge, the effects of these guidelines on clinical
ractices and their current relevance have not been
ssessed. Practices in Canada were evaluated before
evelopment of the CDC guidelines in a published
ational survey [23]. The original survey provided a
nique opportunity to describe the change in practices
mong transplant centers in Canada and to compare
urrent practices with CDC guideline recommenda-
ions.
In accordance with CDC recommendations, all 21
llogeneic HSCT programs documented donor and
ecipient CMV serologic status before HSCT (AI;
ppendix 1). This allowed the identiﬁcation of pa-
ients who were at increased risk for CMV disease. In
ontrast, 4 (16%) of 25 autologous HSCT programs
all adult) did not routinely test pretransplantation
MV serologic status (AI; Appendix 1). Although
MV disease seems to be less common after autolo-
ous HSCT, published estimates suggest that CMV
isease may occur in up to 7% of patients [11]. How-
ver, most Canadian autologous HSCT centers per-
orm relatively small numbers of transplantations each
ear. Consequently, CMV disease is infrequently en-
ountered at single institutions, and its overall effect
ay be underestimated. High-risk subgroups include
atients with (1) an underlying hematologic malig-
ancy, (2) graft manipulation before HSCT, (3) highly
able 7. Adherence to CDC Guideline Recommendations at Canadian
CDC Recommendations
ecipients should have pretransplantation CMV serology perform
outine use of CMV-negative blood products is not required but
be appropriate in high-risk patients
igh-risk patients should be evaluated for preemptive therapy
MV pp65 antigenemia or PCR-based assays are preferred moni
tests if preemptive therapy is used
urveillance should continue for 60 days in high-risk recipients
MV infection should be treated with IV ganciclovir or foscarnet
rophylaxis with high-dose acyclovir is not effective in preventing
CMV disease
/A indicates not applicable.
See Appendix 1.
Both centers using preemptive therapy adhered to CDC guideline
and treatment of CMV infection.mmunosuppressive conditioning regimens, and (4) w
92ecent treatment with ﬂudarabine [25-28]. In Canada,
any recipients have 1 or more of these risk factors.
urthermore, more autologous than allogeneic
SCTs are performed annually in Canada (758 versus
55; 2001 Canadian Blood and Marrow Transplant
roup statistics). Thus, although it is proportionally
ot as common in comparison to the allogeneic set-
ing, a clinically important number of patients may be
t increased risk for CMV disease after autologous
SCT in Canada. Therefore, it would seem logical to
est CMV serologic status for all patients before au-
ologous HSCT (performed by 79% of autologous
enters in our survey).
All allogeneic HSCT programs in Canada used
MV-negative blood products to reduce the risk of
ransfusion-transmitted CMV infection. CMV-nega-
ive blood products are used in D/R and/or D/R
erologic pairs at most centers (89%). Administration
f CMV-negative blood products to D/R pairs is
upported by CDC recommendations that state that
eronegative recipients of a seronegative donor should
eceive either CMV-negative or leukodepleted blood
roducts (AI; Appendix 1). In Canada, cellular blood
roducts have been universally leukocyte-reduced
ince 1998. The magnitude of beneﬁt achieved by
ransfusing CMV-negative, in addition to leukocyte-
educed, blood products to at-risk donor-recipient
airs has not been fully evaluated. However, several
tudies—including prospective and randomized, con-
rolled studies—suggest that leukocyte-reduced blood
roducts greatly reduce, but do not eliminate, the risk
f transfusion-transmitted CMV infection and disease
29-31]. Furthermore, results from a recent prospec-
ive cohort study that evaluated CMV-seronegative
ecipients of allogeneic HSCT showed a higher rate of
ransfusion-transmitted CMV infection during an era
hen the use of leukocyte-reduced blood products
ous HSCT Centers: 1999 Versus 2002
Adherence to
Recommendation
(1999 Survey) (%)
Adherence to
Recommendation
(2002 Survey) (%)
Quality of Evidence
Supporting
Recommendation*
81 84 AI
63 64 CIII
6 8 CIII
N/A 100† BII
N/A 100† BII
N/A 100† BII
N/A 4 DII
mendations for preferred monitoring test, duration of surveillance,Autolog
ed
may
toring
recomas escalating [32]. Transfusion of ﬁltered red blood
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Bell units from CMV-seropositive donors was a statis-
ically signiﬁcant, independent predictor of transfu-
ion-transmitted CMV infection in this high-risk
atient population. Therefore, transfusion of leuko-
yte-depleted, CMV-seronegative blood products
ay provide an additive beneﬁt and is a reasonable
ractice for at-risk patients in the allogeneic setting,
specially in seronegative recipients of a seronegative
onor (D/R pairs). In Canada, these practices are
lso supported by a published national consensus
tatement [33].
In the setting of autologous HSCT, 18 programs
72%) administered CMV-negative blood products to
ransplant recipients, mostly to CMV-seronegative re-
ipients. These transfusion practices are conservative
ompared with CDC recommendations, which cite no
equirement for the routine use of CMV-negative or
eukocyte-reduced blood products after autologous
SCT, although their use can be considered for
MV-seronegative recipients. Because the risk of
MV disease is substantially lower in autologous
SCT recipients, the potential beneﬁt of CMV-sero-
egative blood in addition to leukocyte-reduced prod-
cts is likely to be small. However, even in the setting
f autologous HSCT, CMV disease carries a poor
rognosis, with mortality rates estimated at 25% to
0% [10,11]. Thus, it may be reasonable to administer
MV-seronegative, leukocyte-reduced blood prod-
cts to seronegative recipients of autologous HSCT,
specially in high-risk patients.
At-risk recipients of allogeneic HSCT should be
reated with prophylaxis or preemptive therapy from
he time of engraftment until at least 100 days after
ransplantation to decrease the risk of CMV disease,
ccording to CDC recommendations (AI; Appendix
). Preemptive therapy may be preferred, particularly
n CMV-seronegative recipients of a seropositive do-
or, in whom the rate of CMV infection is expected to
e low. In our survey, all allogeneic HSCT programs
dhered to this recommendation; 4 programs (19%)
sed prophylaxis, whereas 17 (81%) administered pre-
mptive therapy. In contrast, a minority of autologous
SCT programs used either prophylaxis (8%) or pre-
mptive strategies (8%) to prevent CMV disease de-
pite recommendations that it be considered in high-
isk recipients (CIII; Appendix 1). Despite being used
t 2 centers, high-dose acyclovir and IVIG prophylaxis
re ineffective interventions for the prevention of
MV disease, and these practices did not adhere to
he CDC recommendations (DII; Appendix 1).
Most allogeneic and autologous HSCT programs
hat performed CMV surveillance administered gan-
iclovir as ﬁrst-line treatment for CMV infection.
his was consistent with CDC recommendations
BIII; Appendix 1). Although IV ganciclovir is effec-
ive for the prevention of CMV disease, it is not an s
B&MTdeal drug in this regard because of its signiﬁcant
ematologic toxicity and inconvenient route of ad-
inistration. IV foscarnet and oral valacyclovir have
ecently been compared with IV ganciclovir in sepa-
ate randomized controlled trials according to a pre-
mptive and prophylactic approach, respectively
34,35]. No difference in the incidence of CMV dis-
ase was detected in either study, and both foscarnet
nd valacyclovir were associated with signiﬁcantly less
ematologic toxicity. Although this is promising, ad-
itional clinical trials are necessary before IV ganci-
lovir (monotherapy) is supplanted by an alternative
gent or combination therapy as the routine ﬁrst-line
reatment of CMV infection.
All programs monitored patients after allogeneic
SCT for the development of CMV infection.
creening tests with high sensitivity, such as CMV
p65 antigenemia and PCR of CMV DNA from
lasma or peripheral blood leukocytes, have been pro-
pectively validated and have replaced culture-based
ssays at most centers [36-44]. Most programs used
ither CMV pp65 antigenemia or PCR-based assays
or this purpose, either individually or as part of a
ybrid monitoring strategy. These practices reﬂect
urrent guideline recommendations, which acknowl-
dge that CMV pp65 antigenemia, CMV DNA PCR,
nd BAL have all been validated in clinical studies and
re endorsed as potential monitoring strategies by the
DC. CMV pp65 antigenemia may be preferred be-
ause of a higher positive predictive value [41,44].
AL may be less desirable because of several factors:
he procedure is invasive, results take longer to gen-
rate, and it is not practical to monitor patients serially
hroughout the entire period of risk. Consistent with
his recommendation, approximately half of Canadian
rograms used CMV antigen for detecting CMV in-
ection. Only 1 program, which used NASBA, did not
se 1 of the recommended tests. Although tests other
han those recommended by the CDC may be appro-
riate for surveillance monitoring of CMV infection
including NASBA), there was insufﬁcient evidence
or the CDC to generate speciﬁc recommendations
egarding their utility [41,44-46].
Only 3 programs (12%) routinely monitored for
MV infection after autologous HSCT. CMV pp65
nd PCR-based assays were predominately used, and
onitoring continued for 180 days at 2 centers. The
DC suggested that it might be appropriate to mon-
tor patients who are at particularly high risk for CMV
isease according to a preemptive strategy until day 60
BII; Appendix 1). The incidence of CMV disease
fter autologous HSCT in Canada is not clear. How-
ver, it is anecdotally believed to be a rare complica-
ion, and this notion likely contributes to the lack of
ystematic monitoring at most centers. In addition,
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2he paucity of clinical data published after the CDC
uidelines precludes the development of deﬁnitive
ecommendations with regard to prevention of CMV
isease after autologous HSCT.
Considerable variability existed among allogeneic
SCT programs regarding the optimal duration of
reatment for CMV infection and posttransplantation
MV monitoring. Most Canadian allogeneic pro-
rams provided shorter courses of treatment for CMV
nfection than the CDC guidelines suggest: “after pre-
mptive treatment has been started, maintenance gan-
iclovir is usually continued until 100 days after
SCT or for a minimum of 3 weeks, whichever is
onger (AI).”[24] However, since publication of the
DC guidelines, a number of observations have pro-
ided ancillary support for shorter courses of ganci-
lovir therapy. First, a recently completed random-
zed, controlled trial evaluated a preemptive approach
hat compared IV ganciclovir and IV foscarnet admin-
stered for 14 days [34]. After 2 weeks of therapy,
atients who tested negative for CMV infection
CMV pp65 antigenemia or PCR of blood leukocytes)
eturned to a weekly surveillance program, whereas
hose with persistent CMV infection received addi-
ional maintenance therapy. The incidence of CMV
isease in this study was similar to previous estimates
btained from trials that evaluated longer courses of
reatment (both prophylaxis and preemptive therapy).
econd, the proportion of CMV disease that occurs
ore than 3 months after HSCT (ie, delayed CMV
isease) may be increasing. A variety of factors can
redict those patients at highest risk for delayed CMV
isease, including a low CD4 T-cell count, absolute
ymphopenia, a reduction or absence of speciﬁc anti-
MV cytotoxic T-cell responses, and graft-versus-
ost disease [47]. Prolonged administration of ganci-
lovir may be associated with delayed recovery of
peciﬁc anti-CMV T cell–mediated immunity and
ay predispose patients to delayed CMV disease;
owever, the latter issue is controversial [48,49].
hird, the competing toxicity of ganciclovir-associ-
ted neutropenia may be associated with an increased
ncidence of infection-related morbidity. Shorter
ourses of ganciclovir treatment may reduce these
omplications. Continued monitoring with tests that
re sensitive and have high negative predictive values
CMV pp65 antigenemia and PCR-based assays) are
ppropriate if shorter courses of therapy are to be
dministered. Thus, shorter courses of preemptive
herapy seem to be effective and may be safer because
f less delayed CMV disease and hematologic toxicity.
Monitoring for CMV infection should continue
or at least 100 days after allogeneic HSCT, according
o CDC recommendations (AI; Appendix 1). In Can-
da, more than half of allogeneic programs monitored
or longer than 100 days either routinely (28%) or in m
94he presence of risk factors for late CMV disease
36%). The remaining programs (33%) stopped mon-
toring at day 100 after transplantation even though
DC recommendations suggest ongoing twice-
onthly surveillance in high-risk patients. Deﬁnitive
tudies to guide optimal prevention and treatment of
ate CMV disease are lacking. Our survey did not
ssess how Canadian transplant centers manage late
MV infection.
CMV disease is a dreaded complication of HSCT.
he CDC guidelines did not deﬁne a preferred ap-
roach for the treatment of CMV disease. In our
urvey, most HSCT programs (65%) used ganciclovir
lone, compared with ganciclovir in combination with
VIG (35%). Currently, there are no randomized,
ontrolled trials comparing these 2 treatment ap-
roaches. Evidence supporting combination therapy
ganciclovir and IVIG) is derived mainly from cohort
tudies and compared with historical controls. It is
ossible that better supportive care modalities and
arlier diagnosis account for the improved survival in
ore recent studies. However, given the poor out-
ome of patients and little evidence to suggest harm, it
s reasonable to use combination therapy for patients
ho develop CMV disease.
In conclusion, current practices at Canadian
SCT centers generally comply with CDC recom-
endations. Compared with the practices of Canadian
SCT programs in 1999, more centers are now using
DC-recommended surveillance tests and treatment
ie, ganciclovir) for CMV infection. Overall, the
hange suggests a positive effect of the CDC guide-
ines. Discrepancies between current practices and
DC guidelines tended to occur when evidence sup-
orting a recommendation was poor. In some in-
tances, deviations from guideline recommendations
ere supported by evidence that became available
fter publication of the guidelines. Ongoing variability
n clinical practices suggests an urgent need for well-
esigned clinical trials to clarify a variety of unre-
olved issues, including (1) the optimal duration of
ntiviral therapy once preemptive treatment is initi-
ted; (2) strategies to prevent and manage delayed
MV disease; (3) the role of CMV-negative blood
roducts for recipients of HSCT in the setting of
niversal leukocyte depletion; (4) optimal manage-
ent for the prevention of CMV disease after autol-
gous HSCT; and (5) optimal agents for the preven-
ion of CMV disease (including immunotherapy).
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ppendix 1. Evidence-Based Rating System
Category Definition Recommendation
ystem used to determine strength of recommendation
A Strong evidence for efficacy and
substantial clinical benefit
Strongly
recommended
B Strong or moderate evidence
for efficacy, but only limited
clinical benefit
Generally
recommended
C Insufficient evidence for efficacy
or efficacy does not outweigh
possible adverse consequences
(eg, drug toxicity or
interactions) or cost of
chemoprophylaxis or
alternative approaches
Optional
D Moderate evidence against
efficacy or for adverse
outcome
Generally not
recommended
E Strong evidence against efficacy
or for adverse outcome
Never
recommended
ystem used to determine quality of evidence supporting
recommendation
I Evidence from at least 1 well-executed randomized,
controlled trial
II Evidence from at least 1 well-designed clinical trial
without randomization: cohort or case-controlled
analytic studies (preferably from more than 1
center): multiple time-series studies; or dramatic
results from uncontrolled experiments
III Evidence from opinions of respected authorities
based on clinical experience, descriptive studies,
or reports of expert committeesB&MTEFERENCES
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